TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
Signum Life Science AS
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
1,925
|
1,923
|
1,949 |
| Financial expenses |
10
|
11
|
7 |
| Earnings before taxes |
137
|
-42
|
3 |
| Total assets |
1,027
|
1,010
|
1,178 |
| Current assets |
727
|
607
|
761 |
| Current liabilities |
228
|
303
|
374 |
| Equity capital |
793
|
692
|
777 |
| - share capital |
169
|
178
|
190 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
77.2%
|
68.5%
|
66.0% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
7.1%
|
-2.2%
|
0.2% |
| Return on assets (ROA) |
14.3%
|
-3.1%
|
0.8% |
| Current ratio |
318.9%
|
200.3%
|
203.5% |
| Return on equity (ROE) |
17.3%
|
-6.1%
|
0.4% |
| Change turnover |
100
|
98
|
-44 |
| Change turnover % |
6%
|
5%
|
-2% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.